438 related articles for article (PubMed ID: 22818908)
1. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
3. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Pirker R; Minar W; Filipits M
Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
7. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
[TBL] [Abstract][Full Text] [Related]
8. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
10. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy.
Tortora G; Gelardi T; Ciardiello F; Bianco R
Int J Biol Markers; 2007; 22(1 Suppl 4):S47-52. PubMed ID: 17520581
[TBL] [Abstract][Full Text] [Related]
11. Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Ng K; Zhu AX
Crit Rev Oncol Hematol; 2008 Jan; 65(1):8-20. PubMed ID: 18006328
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
13. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Janjigian YY; Azzoli CG; Krug LM; Pereira LK; Rizvi NA; Pietanza MC; Kris MG; Ginsberg MS; Pao W; Miller VA; Riely GJ
Clin Cancer Res; 2011 Apr; 17(8):2521-7. PubMed ID: 21248303
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
Sheng Q; Liu J
Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
17. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]